AMOTL1: Angiomotin-Like 1, Transcript Variant 1 (G154810)

Target Name: AMOTL1

NCBI ID: G154810

AMOTL1

AMOTL1: Angiomotin-Like 1, Transcript Variant 1

AMOTL1, also known as Angiomotin-like 1, transcript variant 1, is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and heart. Its primary function is to regulate the blood vessels, which is essential for maintaining proper circulation and oxygenation of tissues. Unfortunately, AMOTL1 has also been associated with a number of diseases, including cancer, diabetes, and cardiovascular disease. As a result, AMOTL1 has emerged as a promising drug target and a potential biomarker for a variety of diseases.

AMOTL1 was first identified in the late 1990s using transcriptomics techniques. The gene encodes a protein that is similar to the protein known as SMAD4, which is a transcription factor that is involved in regulating gene expression. SMAD4 is a transcription factor that is expressed in various tissues and has been implicated in a number of diseases, including cancer, cardiovascular disease, and autoimmune disorders.

AMOTL1 is a transmembrane protein that is expressed in the endothelial cells, which are the cells that line the blood vessels. It is involved in the regulation of various processes that are critical for maintaining the integrity of blood vessels, including cell signaling, migration, and angiogenesis.

One of the most significant functions of AMOTL1 is its role in regulating angiogenesis, which is the process by which new blood vessels are formed in the body. Angiogenesis is a critical process for maintaining the blood supply to the body's various tissues and is essential for maintaining proper circulation and oxygenation.

AMOTL1 is involved in the regulation of angiogenesis by controlling the activities of several key genes that are involved in the process. For example, AMOTL1 has been shown to regulate the activity of the gene PDGF2, which is involved in promoting angiogenesis. Additionally, AMOTL1 has been shown to regulate the activity of the gene PDGF2, which is involved in promoting angiogenesis. has been shown to regulate the activity of the gene FGF1, which is involved in the regulation of cell signaling and migration.

AMOTL1 is also involved in the regulation of cell signaling and migration, which are critical processes that are essential for the development and maintenance of tissues. For example, AMOTL1 has been shown to regulate the activity of the protein FAK, which is involved in cell signaling and has been implicated in a number of diseases, including cancer and cardiovascular disease.

In addition to its role in regulating angiogenesis, AMOTL1 is also involved in the regulation of cellular processes that are critical for maintaining the integrity of blood vessels. For example, AMOTL1 has been shown to regulate the activity of the enzyme NADPH, which is involved in the production of reactive oxygen species (ROS) that can damage blood vessels and contribute to the development of cardiovascular disease.

AMOTL1 is also involved in the regulation of the immune response, which is a critical process for maintaining the health and integrity of the body. For example, AMOTL1 has been shown to regulate the activity of the T-cell, which is a key immune cell that is involved in fighting off infections and promoting the growth and development of tissues.

AMOTL1 is a transmembrane protein that is expressed in various tissues throughout the body. Its primary function is to regulate the blood vessels and the processes that are critical for maintaining the integrity of these vessels. While more research is needed, AMOTL1 is a promising drug target and a potential biomarker for a variety of diseases.

Protein Name: Angiomotin Like 1

Functions: Inhibits the Wnt/beta-catenin signaling pathway, probably by recruiting CTNNB1 to recycling endosomes and hence preventing its translocation to the nucleus

The "AMOTL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMOTL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets